Table 3.
Completed clinical trials based on monotherapy with anti-PD-1/PD-L1 therapy for renal cell carcinoma (RCC) registered in ClinicalTrials.gov (June 2022)
| Agents | Phase | Participant number | Allocation | Dose | Location | NCT number |
|---|---|---|---|---|---|---|
| Nivolumab | 2 | 730 | N/A | 3 mg/kg | France | NCT03013335 |
| Nivolumab | 1 | 17 | N/A | 3 mg/kg | USA | NCT02575222 |
| Nivolumab | 4 | 197 | N/A | 3 mg/kg | USA | NCT02596035 |
| Nivolumab | 3 | 1068 | Randomized | 3 mg/kg | International | NCT01668784 |
| Nivolumab | 2 | 68 | Randomized | 0.3–10 mg/kg | International | NCT01354431 |
| Nivolumab | 1 | 395 | Non-Randomized | 0.1–10 mg/kg | USA | NCT00730639 |
| Nivolumab | 1 | 39 | Non-Randomized | 0.3–10 mg/kg | USA | NCT00441337 |
| Pembrolizumab | 2 | 275 | Non-Randomized | 200 mg | UK | NCT02853344 |
NA